Business
Eupraxia Pharmaceuticals Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$22,287,125
Eupraxia Pharmaceuticals Announces Closing of Non-Brokered Private Placement for Gross Proceeds o...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$22,287,125\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n /NOT FOR DISSEMINATION IN\n \n THE UNITED STATES\n \n OR THROUGH U.S. NEWSWIRE SERVICES/\n \n \n \n \n \n VICTORIA, BC\n \n \n ,\n \n \n Aug. 18, 2023\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, is pleased to announce that it has closed the previously announced non-brokered private placement and has issued 3,183,875 common shares (the \"Common Shares\") of the Company, at a price of\n \n C$7\n \n .00 per Common Share for gross proceeds of\n \n C$22,287\n \n ,125 (the \"Private Placement\").\n \n \n The Company intends to use the net proceeds from the Private Placement towards the Company's ongoing research and development activities, including the clinical development of EP-104IAR, other preclinical and clinical targets as well as for working capital and general capital purposes.\n \n \n This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in\n \n the United States\n \n or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in\n \n the United States\n \n absent registration or an applicable exemption from the registration requirements thereunder.\n \n \n \n \n About Eupraxia Pharmaceuticals Inc.\n \n \n \n \n Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia's product candidates has the potential to address therapeutic areas with high unmet medical need and strives to provide improved p...